Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Smoking and obesity remain major public health challenges in Türkiye, with one-third of the population smoking and over half ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Nonalcoholic fatty liver disease (NAFLD) was linked to elevated liver enzymes in type 2 diabetes mellitus (T2DM) in a recent ...

As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...